Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.51 |
| ▸ | RAB9A | P51151 | 4/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.51 |
| ▸ | GAA | P10253 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA4 | P22748 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28451989 | 0.84 | CA12 (0.50) | ALDH1A1KMT2ASMN1; SMN2MEN1MAPT | |
| SCHEMBL226117 | 0.84 | POLB (0.64) | ALDH1A1KMT2ASMN1; SMN2GAAMEN1 | |
| SCHEMBL9669181 | 0.84 | HTT (0.55) | ALDH1A1HTTKMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL709788 | 0.82 | POLB (0.68) | ALDH1A1HTTKMT2ARAB9AGAA | |
| SCHEMBL29391544 | 0.82 | POLB (0.68) | ALDH1A1HTTKMT2ARAB9AGAA | |
| SCHEMBL26622207 | 0.82 | HTT (0.53) | ALDH1A1HTTKMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL3066455 | 0.82 | CA12 (0.48) | ALDH1A1HTTKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL5271262 | 0.81 | ALDH1A1 (0.50) | ALDH1A1HTTKMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL515125 | 0.80 | HTT (0.51) | ALDH1A1HTTKMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL3078654 | 0.80 | HTT (0.51) | ALDH1A1HTTKMT2ARAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5041567-A | Human and veterianary medicine; veneral diseases respiratory diseases, bovine mastitis | BEECHAM GROUP PLC (GB) | 1991-08-20 | — | — | US | claimed |
| US-11872206-B2 | Purified forms of rofecoxib, methods of manufacture and use | Tremeau Pharmaceuticals, Inc. (US) | 2024-01-16 | — | — | US | disclosed |
| US-11872206-B2 | Purified forms of rofecoxib, methods of manufacture and use | Tremeau Pharmaceuticals, Inc. (US) | 2024-01-16 | — | — | US | disclosed |
| US-20230348524-A1 | TECHNOLOGIES FOR OLIGONUCLEOTIDE PREPARATION | WAVE LIFE SCIENCES LTD. (SG) | 2023-11-02 | — | — | US | disclosed |
| US-11617735-B2 | Purified forms of rofecoxib, methods of manufacture and use | Tremeau Pharmaceuticals, Inc. (US) | 2023-04-04 | — | — | US | disclosed |
| US-11576890-B2 | Purified forms of rofecoxib, methods of manufacture and use | Tremeau Pharmaceuticals, Inc. (US) | 2023-02-14 | — | — | US | disclosed |
| US-11576890-B2 | Purified forms of rofecoxib, methods of manufacture and use | Tremeau Pharmaceuticals, Inc. (US) | 2023-02-14 | — | — | US | disclosed |
| US-11559509-B2 | Purified forms of rofecoxib, methods of manufacture and use | Tremeau Pharmaceuticals, Inc. (US) | 2023-01-24 | — | — | US | disclosed |
| US-11559509-B2 | Purified forms of rofecoxib, methods of manufacture and use | Tremeau Pharmaceuticals, Inc. (US) | 2023-01-24 | — | — | US | disclosed |
| US-20220409568-A1 | PURIFIED FORMS OF ROFECOXIB, METHODS OF MANUFACTURE AND USE | Tremeau Pharmaceuticals, Inc. (US) | 2022-12-29 | — | — | US | disclosed |
| US-6391870-B2 | DOPAMINERGIC AGENT | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2002-05-21 | — | — | US | disclosed |
| US-20020006921-A1 | Pyrrolo {2,1-b}{1,3}benzothiazepines with atypical antipsychotic activity | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2002-01-17 | — | — | US | disclosed |
| EP-1100803-A2 | PYRROLO 2,1-B] 1,3]BENZOTHIAZEPINES WITH ATYPICAL ANTIPSYCHOTIC ACTIVITY | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 2001-05-23 | — | — | EP | disclosed |
| WO-2000006579-A2 | PYRROLO[2,1-B][1,3]BENZOTHIAZEPINES WITH ATYPICAL ANTIPSYCHOTIC ACTIVITY | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2000-02-10 | — | — | WO | disclosed |
| CN-1204318-A | Aromatic thioether acylation method | RHODIA CHIMIE SA (FR) | 1999-01-06 | — | — | CN | disclosed |
| WO-1996036617-A1 | SUBSTITUTED OXAZOLES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-11-21 | — | — | WO | disclosed |
| EP-0699192-A1 | SUBSTITUTED OXAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-03-06 | — | — | EP | disclosed |
| WO-1994027980-A1 | SUBSTITUTED OXAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1994-12-08 | — | — | WO | disclosed |
| EP-0019450-B1 | PYRIMIDINE DERIVATIVES AND THEIR PRODUCTION AND AGRICULTURAL USES | Takeda Chemical Industries, Ltd. (JP) | 1983-02-23 | — | — | EP | disclosed |
| EP-0019450-A1 | Pyrimidine derivatives and their production and agricultural uses | Takeda Chemical Industries, Ltd. (JP) | 1980-11-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11872206-B2 | Purified forms of rofecoxib, methods of manufacture and use | ITGA2B, F13B, F11 | ALDH1A1 2666/4885HTT 4081/4885KMT2A 1173/4885 |
| US-11617735-B2 | Purified forms of rofecoxib, methods of manufacture and use | ITGA2B, F13B, F11 | ALDH1A1 2666/4885HTT 4081/4885KMT2A 1173/4885 |
| US-11559509-B2 | Purified forms of rofecoxib, methods of manufacture and use | ITGA2B, F13B, F11 | ALDH1A1 2666/4885HTT 4081/4885KMT2A 1173/4885 |
| US-11576890-B2 | Purified forms of rofecoxib, methods of manufacture and use | ITGA2B, F13B, F11 | ALDH1A1 2666/4885HTT 4081/4885KMT2A 1173/4885 |
| US-20220409568-A1 | PURIFIED FORMS OF ROFECOXIB, METHODS OF MANUFACTURE AND USE | ITGA2B, F13B, F11 | ALDH1A1 2666/4885HTT 4081/4885KMT2A 1173/4885 |
| US-20230348524-A1 | TECHNOLOGIES FOR OLIGONUCLEOTIDE PREPARATION | POLRMT, DCLRE1B, RNGTT | ALDH1A1 3318/4885HTT 359/4885KMT2A 1707/4885 |
| US-20020006921-A1 | Pyrrolo {2,1-b}{1,3}benzothiazepines with atypical antipsychotic activity | GABRE, GRIN2B, DRD1 | ALDH1A1 838/4885HTT 649/4885KMT2A 1090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.